Diabetes Type 2

A pivotal study with 40-year follow-up of post-bariatric surgery patients reinforces long-term benefits of the procedures on all-cause and cause-specific mortality.

Your daily dose of clinical news you may have missed.

Bexagliflozin significantly improved glycemic control in adults when used as monotherapy, in combination with metformin, or when added to several SOC regimens.

Adults with T2D may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to findings from a retrospective analysis.

Investigators report a 30% reduced risk of total joint replacement in persons with type 2 diabetes treated with metformin vs those who did not receive the drug.

The update removes a previous limitation that stated semaglutide should not be used as an initial therapy for treating patients with T2D.

Diabetes cases in the US among those younger than age 20 years, if left unchecked, are projected to increase by more than 600% by 2060, according to new projections.

A global prevalence of osteoporosis among persons with T2D of more than 25% calls for greater focus on screening for and managing the bone loss disease in this population.

Optimal glycemic control (less than 7%) in participants from the Look AHEAD trial was associated with smaller increases in frailty index score vs poorer control over the 8-year study period.

Find a compact sampling of 2022 research on type 2 diabetes and its treatment reviewed on Patient Care, chosen by the editorial staff.